Amgen reports higher Q3 revenue, EPS and maintains 2026 guidance

Amgen’s third-quarter 2026 revenue rose 8% year over year to $10.4 billion, while GAAP diluted EPS increased 19% to $7.08 and non-GAAP diluted EPS rose 14% to $6.45; free cash flow was $3.7 billion, down from $4.2 billion a year earlier. The company maintained its 2026 guidance for revenue of $38.9 billion to $39.7 billion, GAAP EPS of $18.34 to $19.28 and non-GAAP EPS of $22.90 to $23.70; Prolia and XGEVA sales fell 45% and 47%, respectively, as biosimilars launched globally, while newer products including Repatha, UPLIZNA and IMDELLTRA posted strong growth.